Results 261 to 270 of about 611,323 (305)

Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California.

Clinical Infectious Diseases, 2022
BACKGROUND Neisseria gonorrhoeae is acquiring increasing resistance to available oral antibiotics, and current screening and treatment approaches have not decreased gonorrhea incidence. Although a gonorrhea-specific vaccine does not exist, N. gonorrhoeae
K. Bruxvoort, J. Lewnard, Lie-Hong Chen, H. Tseng, Jennifer J. Chang, J. Marrazzo, L. Qian   +6 more
semanticscholar   +1 more source

Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents.

Clinical Infectious Diseases, 2021
BACKGROUND From 2017 a state-wide cluster randomized trial was conducted in South Australia to assess the impact of the meningococcal B vaccine 4CMenB on pharyngeal N. meningitidis carriage in adolescents.
M. McMillan, Bing Wang, A. Koehler, Thomas R Sullivan, H. Marshall   +4 more
semanticscholar   +1 more source

Meningococcal Vaccines

Infectious Disease Clinics of North America, 2001
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein, M, Fischer, J W, Tappero   +2 more
openaire   +2 more sources

First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England.

Clinical Infectious Diseases, 2020
BACKGROUND 4CMenB is a protein-based meningococcal group B vaccine but the vaccine antigens may also be present on non-group B meningococci. In September 2015, the UK implemented 4CMenB into the national infant immunisation programme, alongside an ...
S. Ladhani, H. Campbell, N. Andrews, S. Parikh, Joanne White, M. Edelstein, S. Clark, J. Lucidarme, R. Borrow, M. Ramsay   +9 more
semanticscholar   +1 more source

Meningococcal conjugate vaccines

Expert Opinion on Pharmacotherapy, 2004
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
David S. Stephens, Shanta M. Zimmer
openaire   +3 more sources

Bioanalysis of Meningococcal Vaccines

Bioanalysis, 2010
Meningococcal meningitis is feared because of the rapid onset of severe disease from mild symptoms and, therefore, is an important target for vaccine research. Five serogroups, defined by the structures of their capsular polysaccharides, are responsible for the vast majority of disease.
Jun X. Wheeler, Neil Ravenscroft, Christopher Jones   +2 more
openaire   +3 more sources

Meningococcal Vaccines

Current Pharmaceutical Design, 2007
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire   +2 more sources

Meningococcal carriage, meningococcal disease and vaccination

Journal of Infection, 1988
Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%)
R.A. Wall, Musa Hassan-King, Brian Greenwood   +2 more
openaire   +3 more sources